Close Menu

Celera Diagnostics’ head of discovery research talks about FDA leading the charge, the need for biomarker validation, and why the conversation should be about targeted — but not personalized — medicine.

As vice president of discovery research at Celera Diagnostics, John Sninsky has a bird’s eye view of how biomarker-based molecular diagnostics are faring in these early days. GT’s Jeanene Swanson caught up with Sninsky for a chat about biomarker validation, getting diagnostics through FDA and to physicians, and more.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Newsweek discusses the privacy issues raised by digital medicine.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.